Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Qiagen N.V. (QGEN)

Qiagen N.V. (QGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,376,861
  • Shares Outstanding, K 228,203
  • Annual Sales, $ 1,965 M
  • Annual Income, $ 341,300 K
  • 60-Month Beta 0.42
  • Price/Sales 4.77
  • Price/Cash Flow 13.15
  • Price/Book 2.60
Trade QGEN with:

Options Overview Details

View History
  • Implied Volatility 33.92% ( +0.38%)
  • Historical Volatility 25.45%
  • IV Percentile 54%
  • IV Rank 54.10%
  • IV High 51.98% on 11/22/23
  • IV Low 12.63% on 09/19/23
  • Put/Call Vol Ratio 0.05
  • Today's Volume 40
  • Volume Avg (30-Day) 530
  • Put/Call OI Ratio 0.33
  • Today's Open Interest 23,356
  • Open Int (30-Day) 26,478

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate 0.52
  • Number of Estimates 7
  • High Estimate 0.54
  • Low Estimate 0.50
  • Prior Year 0.53
  • Growth Rate Est. (year over year) -1.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
40.53 +1.38%
on 06/26/24
45.12 -8.93%
on 06/10/24
-1.93 (-4.49%)
since 05/28/24
3-Month
39.03 +5.28%
on 04/18/24
46.01 -10.69%
on 05/16/24
-1.90 (-4.42%)
since 03/28/24
52-Week
34.74 +18.28%
on 10/30/23
47.70 -13.86%
on 07/27/23
-3.46 (-7.77%)
since 06/28/23

Most Recent Stories

More News
Qiagen: Q1 Earnings Snapshot

Qiagen: Q1 Earnings Snapshot

QGEN : 41.09 (-0.02%)
3 Unusually Active Call Options to Buy With Just 5% Down

Investors continue to wonder how long stocks will keep moving higher. Friday’s jobs report suggests the economy is much stronger than most people realize, which is good news for stocks.

QGEN : 41.09 (-0.02%)
MSFT : 446.95 (-1.30%)
AAPL : 210.62 (-1.63%)
BRK.B : 406.80 (-0.28%)
NVDA : 123.54 (-0.36%)
Qiagen: Q4 Earnings Snapshot

Qiagen: Q4 Earnings Snapshot

QGEN : 41.09 (-0.02%)
Qiagen: Q3 Earnings Snapshot

Qiagen: Q3 Earnings Snapshot

QGEN : 41.09 (-0.02%)
Qiagen: Q2 Earnings Snapshot

Qiagen: Q2 Earnings Snapshot

QGEN : 41.09 (-0.02%)
Qiagen: Q1 Earnings Snapshot

Qiagen: Q1 Earnings Snapshot

QGEN : 41.09 (-0.02%)
QIAGEN Announces Form 20-F Annual Report Filing for 2022 Results

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December...

QGEN : 41.09 (-0.02%)
QIAGEN and Servier Partner to Develop Companion Diagnostic for Acute Myeloid Leukemia (AML) Therapy Drug

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has entered into a strategic partnership with Servier, a global pharmaceutical group, to develop a companion diagnostic test for...

QGEN : 41.09 (-0.02%)
SOPHiA GENETICS and QIAGEN Forge Partnership to Combine Strengths in Next-generation Sequencing

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space, today announced a new partnership with QIAGEN N.V. (NYSE: QGEN) that will pair QIAseq reagent technology with the...

QGEN : 41.09 (-0.02%)
SOPH : 4.58 (-1.29%)
QIAGEN and SOPHiA GENETICS Forge Partnership to Combine Strengths in Next-Generation Sequencing

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the new QIAseq Platform Partnership program and the first partnership with medical data-analysis provider SOPHiA GENETICS...

QGEN : 41.09 (-0.02%)
SOPH : 4.58 (-1.29%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Bearish.

See More Share

Business Summary

QIAGEN N.V. is one of the world's leading providers of technologies and products for the separation, purification and handling of nucleic acids DNA/RNA. The company provides innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions. It has developed...

See More

Key Turning Points

3rd Resistance Point 42.38
2nd Resistance Point 41.98
1st Resistance Point 41.53
Last Price 41.09
1st Support Level 40.68
2nd Support Level 40.28
3rd Support Level 39.83

See More

52-Week High 47.70
Fibonacci 61.8% 42.75
Fibonacci 50% 41.22
Last Price 41.09
Fibonacci 38.2% 39.69
52-Week Low 34.74

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar